Skip to main content
    N

    NewGenIvf Group Limited Class A Ordinary Shares (NIVF)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $0.20
    -0.03 (-11.33%)

    Market Cap: $369,510

    Last updated: Nov 17, 2026 at 11:03 AM ET

    NewGenIvf Group Limited Class A Ordinary Shares (NIVF) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    NewGenIvf Group Limited Class A Ordinary Shares reported revenue of $4.73M for the fiscal year ended Dec 31, 2025, down 13.0% from the year before. That year, net income was $9.88M with a net margin of 209.0%, operating cash flow was -$10.93M and free cash flow was -$16.68M. The quarter ended Sep 30, 2026 had revenue of $1.92B and net income of -$8.04B.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.73M-13.0%20.2%-226.9%209.0%
    Dec 2024$5.43M+5.8%33.6%-21.4%-9.7%
    Dec 2023$5.14M-13.6%32.7%-49.1%-13.5%
    Dec 2022$5.94M+44.3%25.9%6.7%7.7%
    Dec 2021$4.12MN/A24.9%4.8%0.0%
    Annual, fiscal years ended Dec 2021 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Revenue$4.73M$5.43M$5.14M$5.94M$4.12M
    Cost of revenue$3.77M$3.61M$3.45M$4.41M$3.09M
    Gross profit$955.85K$1.83M$1.68M$1.54M$1.02M
    Operating income-$10.73M-$1.16M-$2.52M$398.70K$198.76K
    Net income$9.88M-$525.00K-$690.85K$458.67K-$533
    EBITDA$10.84M$24.26K-$2.52M$725.69K$587.01K
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Dec 2025Sep 2025Mar 2025Dec 2024Sep 2024Jun 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$1.92B$1.42M$1.28M$1.27M$1.27M$1.47M$1.52MN/AN/AN/AN/AN/A
    Gross profit$464.49M$524.02K$118.02K$539.13K$539.13K$648.83K$196.82KN/AN/AN/AN/AN/A
    Operating income-$3.55B-$4.97M-$2.51M-$1.09M-$1.09M$216.31K$196.82K-$1.27M-$377.72K-$367.00K-$510.55K-$115.64K
    Net income-$8.04B-$7.67M$16.82M-$108.00K-$108.24K-$19.86K$335.63K-$955.49K$127.02K$85.50K$52.12K$474.36K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $4.59M exceeded cash and equivalents by $3.83M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Total assets$32.72M$3.58M$21.32M$2.90M$1.41M
    Current assets$7.38M$3.17M$50.78K$2.40M$820.39K
    Cash and equivalents$758.62K$457.74K$42.22K$27.56K$28.76K
    Total liabilities$6.74M$5.06M$5.72M$2.80M$2.33M
    Short-term debt$494.16K$690.97K$1.62M$203.41K$664.15K
    Long-term debt$4.10M$2.33MN/AN/AN/A
    Shareholder equity$26.63M-$1.05M$15.60M$563.11K-$775.94K
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Dec 2023Sep 2023Jun 2023
    Total assets$36.44M$36.44M$32.72M$35.56MN/A$3.78MN/A$1.47M$4.49M$21.32M$39.34M$1.45M
    Total liabilities$10.72M$10.72M$6.74M$6.82MN/A$5.06MN/A$8.55M$1.24M$5.72M$4.43M$1.50M
    Cash and equivalents$1.02M$1.02M$758.62K$295.29KN/A$457.74KN/A$169.66K$54.10K$42.22K$38.75K$77.29K
    Shareholder equity$26.43M$26.43M$26.63M$29.38MN/A-$844.61KN/A-$6.58M$3.74M$15.60M$34.91M$475.74K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$10.93M-$8.26M-$857.36K-$527.12K$1.43M
    Capital expenditures$5.75M$53.04K$69.85K$94.45K$16.57K
    Free cash flow-$16.68M-$8.32M-$927.20K-$621.58K$1.42M
    Investing cash flow-$7.56M-$53.05KN/A-$69.69M-$16.57K
    Financing cash flow$18.99M$8.68M-$50.41M$70.27M-$1.54M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Mar 2025Dec 2024Sep 2024Jun 2024Dec 2023Sep 2023Dec 2022
    Operating cash flowN/AN/A-$6.35MN/AN/A-$142.71K-$142.71K-$203.28K-$34.67K
    Capital expenditures$0$0$2.82K$0$0N/A$0$0$1
    Free cash flowN/AN/A-$6.36MN/AN/AN/A-$142.71K-$203.28K-$34.67K
    Last 9 quarters

    Frequently Asked Questions About NIVF

    What is NewGenIvf Group Limited Class A Ordinary Shares' annual revenue?

    NewGenIvf Group Limited Class A Ordinary Shares reported revenue of $4.73M for the fiscal year ended Dec 31, 2025.

    How fast is NewGenIvf Group Limited Class A Ordinary Shares' revenue growing?

    Revenue was down 13.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -7.4%.

    Is NewGenIvf Group Limited Class A Ordinary Shares profitable?

    Yes. NewGenIvf Group Limited Class A Ordinary Shares reported net income of $9.88M for the fiscal year ended Dec 31, 2025, with a net margin of 209.0%.

    How much free cash flow does NIVF generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.93M minus capital expenditures of $5.75M produced free cash flow of -$16.68M.

    How much debt does NewGenIvf Group Limited Class A Ordinary Shares have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $4.10M, short-term debt of $494.16K and cash and equivalents of $758.62K.